Usage summary
Strongest role: Inclusion Required
Inclusion-required count: 7
Treatment-assignment count: 1
Stratification count: 0
solid tumor basket · Small Molecule Inhibitor
ALK fusion is flagged as trial selection rising because public trials show inclusion required evidence in 13 contexts. FDA CDx context should be reviewed manually.
Strongest role: Inclusion Required
Inclusion-required count: 7
Treatment-assignment count: 1
Stratification count: 0
Threshold count: 0
Common snippets: None extracted
Threshold label: Low
CDx label: Fda Cdx Context Manual Review Required
CDx maturity score: 2/5
Confidence: Medium
Signal count: 0
Recent signals: 0
Density label: Low
https://clinicaltrials.gov/study/NCT01294202 | https://clinicaltrials.gov/study/NCT02630251 | https://clinicaltrials.gov/study/NCT01441388 | https://clinicaltrials.gov/study/NCT00422682 | https://clinicaltrials.gov/study/NCT03175497 | https://clinicaltrials.gov/study/NCT05172245 | https://clinicaltrials.gov/study/NCT01999972 | https://clinicaltrials.gov/study/NCT05370469 | https://clinicaltrials.gov/study/NCT06322095 | https://clinicaltrials.gov/study/NCT05507541 | https://clinicaltrials.gov/study/NCT03719898 | https://clinicaltrials.gov/study/NCT07238569 | https://clinicaltrials.gov/study/NCT03544723